Background/Aims: We sought to investigate the roles of maximum standardized uptake value (SUV max ) and serum carbohydrate antigen in predicting the histopathological features of periampullary tumors. Materials and Methods: Thirty-four patients with histologically confirmed periampullary tumors were classified into two groups, according to the localizations of their tumors (ampulla Vateri or pancreas). SUV max was obtained from [(18)F]-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT). SUV max and CA 19-9 levels were measured and compared with histopathological features of the tumors. Logistic regression was used to assess the significance and independence of predictive factors. Results: 18F-FDG PET/CT SUV max (<2.5 vs. ≥2.5; p=0.031) and CA 19-9 level (normal vs. elevated; p=0.045) were significantly and independently predictive of the histopathological origin of the tumors (ampulla Vateri vs. pancreas). The ratio of CA 19-9 levels and SUV max were found to be higher in cases of poorly differentiated tumors and tumors greater than 2 cm in diameter. Conclusion: A surgical approach to treatment may be considered for patients who have both i) an established or suspected diagnosis of periampullary tumors and ii) low SUV max and CA 19-9 levels.
INTRODUCTION
Pancreatic cancer is one of the most aggressive malignancies and has an extremely poor prognosis. It is the fourth leading cause of cancer-related death in the Western world, with one-and five-year survival rates of approximately 19% and <5%, respectively (1) . Clinically, patients who have pancreatic cancer usually present with locally advanced, unresectable, or metastatic disease.
Periampullary tumors may arise from structures near the ampulla of Vater (pancreas, common bile duct, duodenum, or the ampulla of Vater itself ) (2) (3) (4) . The prognosis of these tumors may vary according to their origin. Although tumors originating from the ampulla or distal choledochus are characterized by longer durations of survival, complete surgical resection has been shown to be the only means of providing cure. Early and accurate diagnosis is extremely important to both the overall survival and quality of life of patients with periampullary tumors.
Serum carbohydrate antigen is an extensively studied and validated pancreatic cancer biomarker that has been used for the diagnosis and surveillance of periampullary tumors in non-jaundiced patients. CA 19-9 has well-known roles in predicting prognosis, overall survival, response to chemotherapy, and postoperative recurrence (5) (6) (7) (8) (9) (10) (11) .
The maximum standardized uptake value (SUV max ) is a marker of tumor glucose metabolism detected by [18F]-fluorodeoxyglucose (18F-FDG) positron emission tomography/ computed tomography (PET/CT). SUV max reflects tumor aggressiveness and is an independent prognostic factor in pancreatic cancer. Evaluation of SUV max offers an advanced method of detecting small solid lesions, based on the focal uptake of FDGlabeled glucose in malignant tumor cell populations (12, 13) .
Several studies have reported the clinical utility of CA 19-9 levels and PET/CT in the diagnosis and management of periampullary tumors (14) (15) (16) (17) (18) (19) . Although results from these studies have been encouraging, data regarding the link between CA 19-9 levels, SUV max , and confirmed histopathological features are lacking in the current literature on periampullary tumors. In this study, we aimed to investigate the role of CA 19-9 and SUV max in predicting the histopathological features of periampullary tumors.
MATERIALS AND METHODS
This study included 36 patients who had a histologically confirmed or suspected diagnosis of periampullary tumor, and who underwent whole body 18-F FDG PET/CT scans at the Surgical Oncology Unit of the General Surgery Department of Cukurova University Hospital between June 2009 and February 2013. The exclusion criteria included diabetic patients and patients who were inoperable. The study was approved by our institution's ethical committee and written informed consent was obtained from each participant enrolled in the study.
The following laboratory data were recorded for all patients: bilirubin (BIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphate (ALP), gamma-glutamyl transpeptidase (GGT), and CA 19-9 levels. Patients were classified according to the results of the biochemical tests that had been conducted. All of the surgical procedures and microscopic examinations of surgically resected specimens were performed by the same surgical and pathology team. The following additional data were also analyzed in this study: mean diameters of masses in histopathologic specimens, their localizations (ampulla, duodenum, head of pancreas, or distal choledochus), and the presence of lymph node metastases, lymphovascular invasion, and/or perineural invasion. Furthermore, patients were grouped according to tumor localization: group 1 included tumors originating from the ampulla, group 2 included tumors originating from the pancreas, and group 3 included tumors originating from the duodenum or distal choledocus. Because group 3 included an insufficient number of patients (n=2), these patients were excluded from the study. According to the mean diameter of the masses in histopathological specimens, we separated the patients into two groups: those with tumor sizes (diameters) less than 2 cm, and those with tumor size greater than 2 cm. Tumor differentiation was defined as well differentiated (Grade 1), intermediate (Grade 2), or poorly differentiated (Grade 3).
18F-FDG PET/CT:
All patients were asked to fast for at least 4 hours before the procedure. Blood glucose concentrations were measured to ensure that all serum glucose levels were below 144 mg/dL before intravenous injection of 18-FDG. Approximately 370 MBq (10 mCi) of FDG was administered to each patient via the antecubital vein. Patients over 70 kg in weight received a dose of 444 MBq (12 mCi) 18-FDG. After the patients had been placed in a resting position in a closed room, a whole-body image was acquired in approximately 60 minutes, following the administration of 18-FDG. PET scans were acquired on an integrated PET-CT system (Biograph LSO DUO PET-CT Scanner, Siemens, Hoffman Estates, IL, USA), which combines a high-resolution PET scanner for 3-dimensional image acquisition with a dual-detector spiral CT scanner. SUV max was recorded and patients were grouped having either SUV max <2.5 or SUV max ≥2.5.
Statistical analysis
Continuous variables that followed normal distributions are expressed as mean ± standard deviation (SD). Variables that did not follow normal distributions are summarized in terms of their medians and ranges. Categorical variables were analyzed using the chi-square test or Fisher's exact test. Comparisons of normally distributed continuous variables were performed using Student's t-test or one-way analysis of variance (ANOVA). The Mann-Whitney U-test or the Kruskal-Wallis test was used when a variables was not normally distributed. The Cohen's kappa test was used to analyze intra-group correlations. Logistic regression analyses were performed to evaluate the independent risk factors related to tumor origin. All data were entered and analyzed using the Statistical Package for Social Sciences, version 19.0 (SPSS Inc., Chicago, IL, USA). P-values less than 0.05 were considered statistically significant.
RESULTS
A total of 36 patients were enrolled in the study, 34 of whom were included in our analyses. and histological results for cases of ampullary and pancreatic tumor, respectively. The biochemical features of the groups are summarized in Table 1 . Group 1 (tumors originating from the ampulla) included 22 patients and group 2 (tumors originating from the pancreas) included 12 patients. We did not find any statistically significant differences between the groups in terms of preoperative biochemical values (ALT, AST, ALP, and GGT; p>0.05).
The clinical features of the groups are presented in Table 2 . Differentiation was poorer in patients belonging to group 2 than in their counterparts in group 1. Lymph node metastasis (LNM) and perineural invasion (PI) were more common in group 2 than in group 1 (p=0.016 and p=0.027, respectively). The frequency of lymphovascular invasion (LI) did not differ significantly between the two groups. However, higher levels of CA 19-9 and SUV max were observed in group 2 (p=0.002 and p=0.002, respectively) ( Table 2) .
PET/CT SUV max was significantly higher for tumors with intermediate and poor differentiation than for well-differentiated tumors. In addition, SUV max was found to be significantly higher in tumors with perineural invasion than in tumors without perineural invasion (p<0.05). Elevated CA 19-9 and high SUV max were significantly more common in cases of poorly differentiated tumors and tumors with diameters greater than 2 cm (p<0.05)., and kappa levels over 0.50 indicated a good correlation between groups (Table 3 ). Logistic regression analysis showed that SUV max and CA 19-9 levels were significantly and independently associated with tumor localization. Particularly, elevated CA 19-9 and SUV max were associated with an increased probability of the tumor having originated in the pancreas (Table 4) .
DISCUSSION
Periampullary tumors can originate from the ampulla, duodenum, head of the pancreas, or distal choledochus. Notably, tumors originating from ampulla or distal choledochus demonstrate better prognosis. In contrast, pancreatic is usually locally advanced, unresectable, or metastatic at the time of diagnosis. Early and accurate diagnosis is extremely important to the overall survival and quality of life of patients with periampullary tumors (1-4).
Carbohydrate antigen 19-9 is a gold-standard serum marker for the diagnosis of pancreatic cancer in symptomatic patients (5-7). Pre-operative CA 19-9 serum levels may provide important prognostic information in patients with pancreatic cancer. Indeed, they correlate with tumor stage and independently predict overall survival (8) (9) (10) . Unfortunately, non-specific expression in several benign and malignant diseases, false-negative results in the Lewis-negative genotype, and increased falsepositive results in the presence of obstructive jaundice severely limit the clinical utility of serum CA 19-9 levels in the manage- The dependent variable is the origin of the tumor (0= Ampulla, 1= Pancreas). Table 4 . Results of the logistic regression analyses ment of pancreatic cancer (6,7). In our study, lower CA 19-9 levels were observed in patients who belonged to the ampulla group and did not have cholangitis. However, patients belonging to the pancreatic cancer group had higher CA 19-9 levels, a finding that has also been demonstrated in previous studies (5) (6) (7) 11) . On the other hand, we detected a correlation between CA 19-9 levels and SUV max or tumor size As has been shown repeatedly in previous studies, SUV max , tumor differentiation, and tumor size are independently predictive of prognosis. Hence, our study supports the hypothesis that CA 19-9 levels may be useful as a prognostic indicator.
The PET/CT technique is an advanced method of detecting small solid lesions, and is assisted by the focal uptake of FDGlabeled glucose in malignant tumor cell populations (12) (13) (14) (15) . The current literature includes relatively little data regarding the diagnostic role of PET/CT in patients with periampullary tumors (16) (17) (18) (19) . Although the FDG-sensitivity of tumors originating from the pancreas has been reported to be between 88% and 92% (17, (19) (20) (21) (22) (23) (24) (25) , there are limited findings for tumors that originate from the ampulla or distal choledochus (16) (17) (18) .
The pancreatic malignancy has variously been reported to be 2.2, 2.5, 2.8, and 3.0 (20, 22, (26) (27) (28) . In the present study, we used an SUV max threshold of 2.5 in our comparisons of SUV max with the histopathological features of periampullary tumors. In our study, 14 of the 22 ampullary tumors and 1 of the 12 pancreatic tumor did not exhibit SUV max >2.5, and we found that the mean SUV max was significantly higher in the pancreas group than in the ampulla group. Therefore, PET/CT is not a useful tool for the diagnosis of tumors originating from the ampullary region. In fact, low or normal SUV max may be suggestive of ampullary localization of a periampullary mass.
Although combined advanced diagnostics are currently available, these methods have limited abilities to detect periampullary lesions smaller than 2 cm In our study, SUV max was significantly lower for tumors smaller than 2 cm, as compared with tumors larger than 2 cm. Some researchers have emphasized that ampullary tumors less than 1 cm in diameter may not have any SUV max on PET/CT (15, 16, 18, 21) . In the ampulla group, PET/ CT observable SUV max was higher for tumors with diameters greater than 2 cm (15, 22, 25* In several studies of ampullary tumors, PET/CT SUV max was higher for tumors with diameters greater than 2 cm (15, 22, 25) In the present study, we also found an association between tumor size and differentiation.
In our study, tumors in the ampullary group were well or intermediately differentiated. In contrast, the pancreas group only included two patients who had well or intermediately differentiated tumors. There is limited data regarding the correlation between SUV max and tumor differentiation. Interestingly, we were able to demonstrate a direct correlation between SUV max and tumor differentiation. In addition, all of the cases of perineural invasion had poor differentiation, and the presence of perineural invasion was associated with increased SUV max in our data. Although it has been suggested that perineural invasion is prognostic of poor survival (29) , there are no previous data regarding the correlation between perineural invasion and PET/CT SUV max .
Many studies have reported that tumor origin, tumor size, tumor differentiation, CA 19-9 level, and perineural invasion are prognostic factors (25, 29) . The results of our study demonstrate an important association between FDG activity and all of these parameters. We suggest that FDG activity is not only important during diagnosis, but might also be considered to be a new prognostic factor (25, 30) .
In conclusion, preoperative PET/CT and CA 19-9 evaluations of patients with periampullary tumors may contribute to data on the tumor's origin, perineural invasion, and/or differentiation.
Thus, a surgical approach should be considered for patients who are known or suspected to have periampullary tumors, and who have low SUV max and CA 19-9 levels. However, larger prospective randomized studies are needed to support our findings.
